Xeris Biopharma(US:XERS)2026-03-02 21:25Cash Flow - Net cash provided by operating activities increased to $28.6 million for the year ended December 31, 2025, compared to a cash outflow of $37.0 million in 2024, primarily driven by higher product sales [477]. - Net cash used in investing activities was $696.0 thousand for the year ended December 31, 2025, a significant decrease from $4.9 million in cash provided in 2024, due to fewer purchases of short-term investments [478]. - Net cash provided by financing activities was $11.4 million for the year ended December 31, 2025, down from $36.2 million in 2024, influenced by proceeds from stock awards and common shares issuance [479]. - The company reported a net cash inflow of $20.7 million from warrants, offset by a $10.9 million repurchase of common stock for tax withholding [481]. Revenue Recognition - The company recognizes revenue when control of goods is obtained by customers, with revenues recorded at net product sales price after accounting for allowances [486]. - The company participates in federal and state government rebate programs, accruing estimated rebates based on actual average amounts and expected prescriptions [488]. Interest and Debt - Interest income from cash and investments could increase or decrease by approximately $1.0 million annually with a hypothetical one-percentage point change in interest rates [493]. - The company’s long-term debt incurs interest at a floating rate of 6.95%, with a fixed rate of 8.0% on the 2028 Convertible Notes, limiting exposure to interest rate risk [494]. Foreign Currency Impact - Foreign currency exchange rates did not materially affect the company's results for the year ended December 31, 2025 [495].